Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Howell T, Hailey D. Use of In-111 Capromab Pendetide in detecting metastatic prostate cancer. Edmonton: Alberta Heritage Foundation for Medical Research (AHFMR). HTB-5. 1999 Authors' objectives To summarise the effectiveness and cost-effectiveness of In-111 Capromab Pendetide in detecting metastatic prostate cancer.
Authors' conclusions Imaging with In-111 Capromab Pendetide provides an additional method for detection of metastatic disease in prostate cancer.
As the images are difficult to interpret, it would be essential for clinicians to receive appropriate training.
Studies of the diagnostic accuracy of In-111 Capromab Pendetide have achieved moderate results with sensitivity ranging between 44 and 89% and specificity ranging between 67 and 86%.
Indications are that the appropriate role for In-111 Capromab Pendetide is as an adjunct to other diagnostic approaches.
There are no studies which report on its effect on clinical decisions or patient outcomes.
Use of In-111 Capromab Pendetide may be indicated in a small number of selected patients.
Indexing Status Subject indexing assigned by CRD MeSH Diagnostic Imaging; Prostatic Neoplasms /diagnosis Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence 1200, 10405 Jasper Avenue, Edmonton, Alberta, Canada, T5J 3N4. Tel: +1 780 448 4881; Fax: +1 780 448 0018 Email: djuzwishin@ihe.ca AccessionNumber 31998009926 Date bibliographic record published 07/03/2000 Date abstract record published 07/03/2000 |